Kazia Therapeutics Strengthens Scientific Leadership with Appointment of Dr. Sudha Rao as Chief Scientific Officer to Lead Next-Generation Oncology Platform
Rhea-AI Summary
Kazia Therapeutics (NASDAQ: KZIA) appointed Dr. Sudha Rao as Chief Scientific Officer on April 15, 2026. Dr. Rao brings 20+ years of translational epigenetics experience, authorship on high‑impact journals, and lead inventorship on 39 international patents to advance Kazia's integrated oncology platform including paxalisib, NDL2, and MSETC.
She will lead R&D, biomarker strategy, external collaborations, and platform expansion with AI‑guided discovery and spatial/liquid epigenetic precision medicine.
Positive
- Experienced leadership: Dr. Sudha Rao brings 20+ years of translational epigenetics experience
- Strong IP: Lead inventor on 39 international patents
- Platform focus: Advances paxalisib, PD‑L1 degrader (NDL2), and SETDB1 program (MSETC)
Negative
- No financial details or R&D timelines disclosed for NDL2 and MSETC
- Clinical stage and near‑term milestones for new programs not specified
News Market Reaction – KZIA
In the Apr 15 session, KZIA gained 5.71%, reflecting a notable positive market reaction. Argus tracked a peak move of +4.5% during that session. Argus tracked a trough of -19.8% from its starting point during tracking. Our momentum scanner triggered 16 alerts that day, indicating notable trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Apr 13 | Platform in-licensing | Positive | +5.2% | In-licensed first-in-class SETDB1 epigenetic platform with AI-integrated engine. |
| Jan 30 | Preclinical data update | Positive | -3.9% | Reported compelling preclinical data for NDL2 nuclear PD-L1 degrader program. |
| Jan 27 | Clinical trial update | Positive | -9.8% | Shared encouraging preliminary Phase 1b paxalisib responses in metastatic TNBC. |
| Jan 08 | Conference participation | Positive | +1.5% | Flagged strong capital position and pending clinical/translational updates pre-conference. |
| Dec 22 | Listing compliance regained | Positive | -8.0% | Regained full Nasdaq compliance following a $50M private placement financing. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent fundamentally positive updates have often seen mixed or negative next-day price reactions, so today’s gain on a strategic leadership hire contrasts with several prior divergences.
Over the past six months, Kazia has focused on building an integrated oncology platform. Key milestones include regaining full Nasdaq compliance via a $50 million private placement on Dec 22, 2025, a well-capitalized positioning and conference visibility in early Jan 2026, and encouraging Phase 1b paxalisib TNBC data on Jan 27, 2026. Subsequent nuclear PD-L1 degrader data and, most recently on Apr 13, 2026, in-licensing of a first-in-class SETDB1 platform further expanded the pipeline. Today’s CSO appointment strengthens leadership behind these programs.
Key Terms
epigenetic medical
pd-l1 medical
chromatin medical
lsd1 inhibitor medical
pi3k/mtor medical
setdb1 medical
ind-enabling regulatory
tumour microenvironment (tme) medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
Dr. Rao is the scientific originator of the epigenetic framework underlying paxalisib and a pioneer in next-generation therapeutic platforms, including PD-L1 protein degradation and SETDB1-targeted chromatin modulation. Her appointment brings deep expertise in translational epigenetics, AI-guided epi-drug discovery capability, liquid and spatial epigenetic clinical biomarker precision medicine platforms, and early clinical development into Kazia's executive leadership as the Company advances its integrated oncology platform strategy.
Dr. Rao is a highly accomplished translational scientist and biotech executive with more than 20 years of experience spanning pharmaceutical R&D, biotechnology, and early clinical development. She currently holds a professorial appointment and leads the Gene Regulation and Translational Medicine Laboratory at QIMR Berghofer Medical Research Institute and previously held senior scientific roles at Sanofi/Rhône-Poulenc in the
She is the founder and former Chief Scientific Officer of EpiAxis Therapeutics and has advanced first-in-class epigenetic therapeutics from discovery through IND-enabling studies and into early clinical trials, including the first Phase 1b study of an LSD1 inhibitor in metastatic breast cancer. Dr. Rao is lead inventor on 39 international patents and has authored numerous high-impact publications in journals including Science, Nature, and Immunity.
At Kazia, Dr. Rao will lead all research and development activities, advancing the Company's pipeline and expanding its next-generation platform capabilities, including:
- Paxalisib, a brain-penetrant dual PI3K/mTOR inhibitor being developed across oncology indications, including advanced breast cancer;
- NDL2, a novel PD-L1 protein degrader platform designed to target intracellular and nuclear PD-L1 biology; and
- MSETC, a first-in-class SETDB1-targeted epigenetic program aimed at reversing immune evasion at the chromatin level.
Her scientific work has been central to advancing the concept of PI3K/mTOR inhibition as a driver of epigenetic reprogramming, forming the foundation of Kazia's strategy to move beyond pathway inhibition toward therapeutic control of cancer's regulatory drivers.
Dr. John Friend, CEO of Kazia Therapeutics, commented: "Dr. Rao is a leading translational epigenetics scientist, a breast cancer researcher, and the lead inventor behind the intellectual property linking PI3K/mTOR inhibition to epigenetic regulation. As the architect of much of our platform, including paxalisib, NDL2, and MSETC, her appointment allows us to immediately strengthen execution while advancing a more integrated, platform-driven oncology strategy."
"I am excited by the opportunity to advance a next-generation oncology platform at Kazia. PI3K/mTOR is a key driver of tumour growth and a master regulator of epigenetic programs that shape tumour behaviour, the tumour microenvironment (TME), and immune evasion," stated Dr. Rao. "We are building a platform focused on precision targeting and precision medicine, integrating spatial and liquid epigenomics and AI-driven drug discovery to accelerate novel therapies. This includes paxalisib alongside emerging programs such as the PD-L1 degrader and SETDB1-targeting approaches. We aim to enable patient selection, real-time target engagement, and a scalable pipeline with clear clinical translation."
Dr. Rao will also play a key role in advancing Kazia's biomarker strategy, external collaborations, scientific publications, and strategic partnerships, while continuing to expand the Company's platform and pipeline.
For investor and media, please contact Mike Moyer, Managing Director LifeSci Advisors LLC, mmoyer@lifesciadvisors, +1-617-308-4306.
About Kazia
Kazia Therapeutics Limited (NASDAQ: KZIA) is an oncology-focused drug development company, based in
Forward Looking Statements
This announcement may contain forward-looking statements, which can generally be identified as such by the use of words such as "may," "will," "estimate," "future," "forward," "anticipate," or other similar words. Any statement describing Kazia's future plans, strategies, intentions, expectations, objectives, goals or prospects, and other statements that are not historical facts, are also forward-looking statements, including, but not limited to, statements regarding: the anticipated contributions of Dr. Sudha Rao as Chief Scientific Officer; expectations regarding Dr. Rao's leadership of Kazia's research and development activities; the potential of Kazia's three-platform oncology strategy, including paxalisib, NDL2, and MSETC; expectations regarding the advancement of Kazia's pipeline and platform capabilities; the potential of paxalisib, including in advanced breast cancer and other oncology indications; the potential of NDL2 as a PD-L1 protein degrader platform; the potential of MSETC as a SETDB1-targeted epigenetic program; expectations regarding Kazia's biomarker strategy, AI-driven drug discovery, and precision medicine capabilities; and Kazia's broader pipeline strategy and anticipated benefits of its integrated platform approach. Such statements are based on Kazia's current expectations and projections about future events and future trends affecting its business and are subject to certain risks and uncertainties that could cause actual results to differ materially from those anticipated in the forward-looking statements, including risks and uncertainties associated with: the ability to attract and retain key personnel, including Dr. Rao; the development of early-stage therapeutic programs; the risk that preclinical results may not be predictive of clinical results; risks related to regulatory approvals; risks related to Kazia's reliance on third-party collaborators; risks related to intellectual property protection; risks related to the impact of global economic conditions; and risks related to Kazia's ability to maintain compliance with the applicable NASDAQ continued listing requirements and standards. These and other risks and uncertainties are described more fully in Kazia's Annual Report on Form 20-F filed with the SEC, and in subsequent filings with the United States Securities and Exchange Commission. Kazia undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise, except as required under applicable law. You should not place undue reliance on these forward-looking statements, which apply only as of the date of this announcement.
View original content:SOURCE Kazia Therapeutics Limited